Anthracycline-based antineoplastic therapy (standard of care/routine treatment)
Conditions
Brief summary
Changes in the T2-weighted relaxation time in myocardial mapping
Detailed description
Further abnormal CMR findings (morphology, function, perfusion, LGE and residual parametric mapping (T1-weighted relaxation time, extracellular volume)) during and after completion of anthracycline-based chemotherapy, analyzed by two different investigators, Troponin T and NT-proBNP before, during and after completion of anthracycline-based chemotherapy in correlation with CMR results, Echocardiographically determined Global Longitudinal Strain before, during and after completion of anthracycline-based chemotherapy in correlation to CMR results, Validation and/or identification of new biomarkers (e.g. genetic markers) using the biomaterials
Interventions
Sponsors
Robert Bosch Gesellschaft fuer medizinische Forschung mbH
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in the T2-weighted relaxation time in myocardial mapping | — |
Secondary
| Measure | Time frame |
|---|---|
| Further abnormal CMR findings (morphology, function, perfusion, LGE and residual parametric mapping (T1-weighted relaxation time, extracellular volume)) during and after completion of anthracycline-based chemotherapy, analyzed by two different investigators, Troponin T and NT-proBNP before, during and after completion of anthracycline-based chemotherapy in correlation with CMR results, Echocardiographically determined Global Longitudinal Strain before, during and after completion of anthracycline-based chemotherapy in correlation to CMR results, Validation and/or identification of new biomarkers (e.g. genetic markers) using the biomaterials | — |
Countries
Germany
Outcome results
None listed